Arix Bioscience PLC (LON:ARIX) noted that further details of proposals by Harpoon Therapeutics Inc. for an underwritten US initial public offering would represent a £4.2mln-£7.9mln increase in the value of its current shareholding in Harpoon.
The LSE main market-listed global healthcare and life science company supporting medical innovation said that increase was compared to the current £20.2mln value of its holding.
The UK firm pointed out the figures are based on Harpoon’s amended registration statement, filed with the US Securities and Exchange, which discloses an expected pricing range for the proposed offering of US$13.00–US$15.00 per share.
It noted that the proposed maximum aggregate offering amount specified in the filing is US$93.15mln, which assumes that the public offering price is at the top of the expected pricing range and includes the option that is proposed to be granted to the underwriters to purchase additional shares of common stock.
Arix also said it has indicated an interest in purchasing shares of common stock in the offering, subject to agreement with the underwriters.